ZHONGSHENGYAOYE(SZ:002317) GLP1减重宝典·2025-06-25 03:19Core Viewpoint - The article highlights the promising results of RAY1225, a novel GLP-1/GIP dual receptor agonist developed by Zhongsheng Pharmaceutical, showcasing its efficacy and safety in treating overweight, obesity, and type 2 diabetes during the ADA conference [2][5]. Group 1: Clinical Results - RAY1225 demonstrated significant weight loss effects, with an average reduction exceeding 10% in all dosage groups by week 10, and over 15% in the 9mg group by week 24 [2]. - Approximately 95.1% of participants achieved a weight loss of 5% or more by week 24, indicating strong efficacy [2]. - The gastrointestinal side effects associated with RAY1225 were mostly mild, with lower incidence rates of diarrhea, nausea, and vomiting compared to Tirzepatide [3]. Group 2: Administration and Compliance - RAY1225 is administered bi-weekly, which is more convenient than the weekly injection schedule of Tirzepatide, potentially improving patient adherence to the treatment [4]. Group 3: Ongoing Research - The Phase III clinical trial (REBUILDING-2) for RAY1225 has commenced, featuring a multi-center, randomized, double-blind, placebo-controlled design, with ethical approval obtained from relevant institutions [5].